The TRIM family of genes is largely studied because of their roles in development, differentiation and host cell antiviral defenses; however, roles in cancer biology are emerging. Loss of heterozygosity of the TRIM3 locus in B20% of human glioblastomas raised the possibility that this NHL-domain containing member of the TRIM gene family might be a mammalian tumor suppressor. Consistent with this, reducing TRIM3 expression increased the incidence of and accelerated the development of platelet-derived growth factor -induced glioma in mice. Furthermore, TRIM3 can bind to the cdk inhibitor p21 WAF1/CIP1 . Thus, we conclude that TRIM3 is a tumor suppressor mapping to chromosome 11p15.5 and that it might block tumor growth by sequestering p21 and preventing it from facilitating the accumulation of cyclin D1-cdk4.
INTRODUCTION
Glioblastomas (GBM) are among the most common central nervous system tumors, comprisingB25% of adult brain cancers. 1 Despite advances in diagnosis and therapy, the prognosis for patients with malignant glioma remains poor. Although a number of studies have stratified gliomas into distinct groups based on molecular and biochemical profiles, [2] [3] [4] [5] the significance of many of these differences to understanding or treating the disease has yet to be established.
One-third of GBMs are associated with chronic platelet-derived growth factor (PDGF) signaling and have a proneural signature. These tumors are characterized by dysregulation of the Rb signaling pathway, which contributes to excessive cell proliferation, a hallmark of this subtype of glioma. Nevertheless, the genetic heterogeneity within this group suggests that additional changes contribute to the pathogenesis of these tumors and there are likely multiple subtypes, perhaps reflecting different cells of origin. 6, 7 Loss of heterozygosity in chromosomal region 11p15.5 in B20% of human GBM raised the possibility that TRIM3 could be a potential tumor suppressor. 8 The TRIM family members contain a structurally conserved amino terminal RING motif followed by one or two B-boxes and a coiled-coil domain. 9 Distinct subclasses of this family are defined by the presence of other domains following this conserved unit. A few of the members containing SPRY domains, PHD/BROMO domains or TM domains have been implicated in human cancer. 10 TRIM3 is in the NHL domain containing subgroup, which contains three other mammalian paralogs (TRIM2, TRIM32 and TRIM71) and orthologs in both Drosophila melanogaster (Brat, Mei-P26, Abba and Wech), and Caenorhabditis elegans (Ncl-1, and Nhl-1, Nhl-2, Nhl-3, Lin41) (reviewed in the study by Wulczyn et al. 11 ). Of these, only the fly ortholog brat has previously been implicated as a growth suppressor with a role preventing tumor-like proliferation of secondary neuroblasts. 12 Expression of brat is largely restricted to the embryonic peripheral nervous system, ventral nerve cord and the developing brain of the fly. Loss-of-function alleles, including those that eliminate the NHL domain are associated with increased numbers of secondary neuroblasts. Brat promotes asymmetric division that produces ganglion mother cells, which ultimately divide one more time to produce neurons. [13] [14] [15] [16] How the brat mutation leads to increased numbers of secondary neuroblasts is not particularly well understood. 17 Like other TRIM-NHL proteins, brat can interact with Ago1, and microRNA-induced silencing complex effector protein (reviewed in the study by Wulczyn et al. 11 ). Brat, TRIM32 and mei-P26 also regulate the post-transcriptional accumulation of myc, 14, [18] [19] [20] [21] and Brat can interact with numb and prospero to control mRNA localization as well. 15, 16, 18 The contribution of each mechanism to tumor suppression, however, is not clear.
The RCAS-PDGF/nestin-TvA mouse model recapitulates the morphological hallmarks, the dependence on tumor microenvironment, and the stem and progenitor cell behaviors of human proneural PDGF-associated GBM. [22] [23] [24] [25] [26] [27] Additionally, it models the molecular pathways that govern proliferation, differentiation, cell migration, DNA repair and tumor cell-microglia interaction in the microenvironment. [28] [29] [30] [31] [32] Here, we show that TRIM3 has a tumor suppressive role in this model, and it acts in part by regulating the availability of the cdk inhibitor p21, which promotes cyclin D1-cdk4 nuclear accumulation.
RESULTS

TRIM3
, a potential tumor suppressor in human GBM TRIM3 is encoded in the chromosomal locus 11p15.5. Loss of heterozygosity encompassing this region is observed inB20% of human GBM, suggesting that TRIM3 might be a tumor suppressor gene. 8 Supporting this hypothesis of TRIM3 function, the loss of a Drosophilia ortholog of the TRIM-NHL family, brat, results in an increase in the number of secondary neuroblasts at the expense of ganglion mother cells. As comparable progenitors are found in the developing brain of mammals (reviewed by Reichert et al. 12 ), we reanalyzed 203 tumors in the Cancer Genome Atlas study for TRIM3 expression, copy number and mutation. Twenty-six of these tumors had loss of heterozygosity, two of these tumors had homozygous deletion, and three had low-level amplification of this locus. mRNA expression was correlated to gene expression (Figure 1a) . Additionally, in 91 tumors in which the locus was completely sequenced, we identified two nonrecurrent missense mutations (Figure 1a) . One of these, C736Y, is in the NHL domain and the other, G371S, is in the ABP/filamin domain.
To determine whether the expression of TRIM3 was correlated to the presence of the gene, we looked for TRIM3 protein expression by immunoblotting 11 protein extracts prepared from fresh surgical resections, in which the 11p15.5 locus was intact. Strong expression of TRIM3 was seen in only four (Figure 1b) . We identified TRIM3 by comparing its migration with a paired sample of extracts prepared from T98G cells, a human PDGFtransformed glioma cell line, in which TRIM3 was knocked down by a lentiviral small hairpin RNA (shRNA). The nature of the faster migrating anti-TRIM3 reactive band is not clear. This suggests that TRIM3 expression might be reduced more frequently in human GBM than suggested by the genomic data.
TRIM3 is a tumor suppressor in mice The RCAS-PDGF-HA/nestin-TvA model recapitulates a subtype of human proneural GBMs driven by PDGF signaling. To determine whether TRIM3 was a tumor suppressor, we wanted to reduce its expression and ask if that would lead to increased tumor development or accelerate tumor progression in response to PDGF. We first identified RCAS vectors encoding distinct shRNAs that reduced the expression of TRIM3 in YH/J12 cells (Figure 2a) . YH/J12 cells are spontaneously immortalized cells derived by infecting primary brain cultures obtained from nestin-TvA mice with RCAS viral vectors expressing PDGF-HA. These cells are a good ex vivo surrogate of tumor behavior, as they recapitulate the cellular and molecular events during differentiation 25 and proliferation 28, 30 associated with this disease. Notably, reducing TRIM3 correlated with increased proliferation (Figure 2b) .
We subsequently introduced these vectors into nestin-TvA mice with and without RCAS-PDGF-HA. Consistent with the fact that PDGF is the driving oncogene in this model, disease never developed in mice in the absence of RCAS-PDGF-HA. On the other hand, 80% of the mice that were infected with RCAS-PDGF-HA and a scrambled shRNA vector developed tumors, and 100% developed tumors when challenged with RCAS-PDGF-HA and the TRIM3 shRNA vectors (Figure 3a ). TRIM3 protein expression was clearly reduced in the glial cells of the tumor, but not in the trapped neurons ( Figure 3b ). This confirmed the delivery of the shRNA and the cell type specificity of the RCAS system, as well as the specificity of the antibodies to detect TRIM3 by immunohistochemistry. However, although these differences were significant (Po0.05), due to the strong tumor promoting ability of the RCAS-PDGF-HA virus alone, it was difficult to unequivocally conclude that reducing TRIM3 enhanced tumorigenicity.
We reasoned that we might be better able to unmask a tumor suppressive activity of TRIM3 by using a sensitized background. The tumor promoting activity of PDGF is directly proportional to p21 gene dosage. 30 Thus, we repeated this analysis using p21 heterozygous mice and p21-null mice. Whereas 33% of the p21 heterozygous mice coinfected with RCAS-PDGF-HA and a nonspecific shRNA vector developed tumors, 80% of the nestinTvA;p21 þ / À mice coinfected with RCAS-TRIM3 shRNA and RCAS-PDGF-HA developed tumors (Po0.004) (Figure 3a) . Furthermore, there was no morbidity in p21 heterozygous mice expressing PDGF-HA and the scrambled shRNA; however, a significant amount of morbidity was observed in p21 heterozygous animals expressing PDGF-HA and the shRNA against TRIM3 (Figure 3c ). We also found that tumor incidence increased in p21-deficient mice Figure 1 . TRIM3 expression is reduced in some human GBM. (a) Expression of TRIM3 mRNA (y axis) relative to the DNA copy number (x axis) in 203 GBM samples. Data were downloaded from MSKCC's Cancer Genomics Data Portal (http://cbio.mskcc.org/ cancergenomics-dataportal) and samples were separated by the DNA copy number status of 11p15.5 (the TRIM3 containing locus). Deletion and gain calls were determined by the RAE algorithm. 55 Of the 91 samples that were subjected to DNA sequencing, two that exhibited a neutral DNA copy number calls of the 11p15.5 locus contained missense mutations in TRIM3. These mutations, G317S and C736Y and their mRNA expression are indicated in the chart. Figure 3a) . Nevertheless, the incidence of tumors was significantly lower than that observed in the wild-type or heterozygous animals (Po0.01), and the morbidity associated with the tumors was delayed (Figure 3c ). Thus, TRIM3 is a bona fide tumor suppressor and its loss could cooperate with the expression of PDGF to increase the frequency of tumor development and accelerate the morbidity of afflicted animals.
The status of p21 affects the nature of the tumors arising in TRIM3-deficient mice challenged with PDGF The difference in the rate of morbidity associated with the development of proneural GBMs when TRIM3 was reduced in the p21 heterozygous and p21-deficient animals was puzzling. Recently, Barrett et al. 6 showed that tumor cells derived from the RCAS-PDGF-HA/nestin-TvA model could be sorted into two groups based on their Id1 staining. Those that highly expressed Id1 had high self-renewal capacity and generated slow-growing tumors when engrafted into hosts relative to the cells with low Id1 expression, which had limited self-renewal capacity. Thus, given the differences in the onset of morbidity in p21 heterozygous and p21-null mice, in which TRIM3 was reduced, we looked to see if the Id1 staining of the tumors was different. We found strong Id1 staining in 3/3 tumors arising in p21 null mice, whereas only scattered staining was observed in 6/6 p21 heterozygous and wild-type mice. A representative image from each cohort is shown in Figure 3d . Thus, the nature of the tumors that arise in the animals that have p21 is distinct from that in animals that lacked p21, albeit all were proneural GBMs based on morphological and immunohistochemical criteria, as defined by Ciznadijia et al.
(data not shown).
Reducing the expression of TRIM3 increases accumulation of p21 It then occurred to us that the proneural GBMs in this model were exquisitely dose dependent with respect to p21 gene dosage; 30 thus, tumor promoting activity in the p21 heterozygous mice associated with the loss of TRIM3 might be due to increased accumulation of p21. Consistent with this, p21 was barely detectable in extracts from nestin-TvA;p21 þ / À mice infected with RCAS-PDGF-HA alone, but was easily detected in extracts derived from tumor-bearing nestin-TvA;p21 þ / À mice co-infected with the RCAS-PDGF-HA and RCAS-TRIM3 shRNA vectors, even after accounting for oligodendrocyte contribution by normalizing levels to olig2 expression (Figure 4a ). Additionally, p21 protein accumulated in YH/J12 cells, in which TRIM3 protein was reduced following transduction of these shRNA vectors (Figure 2a ), or following transfection with two different small interfering RNAs (Figure 4b ). Thus, reducing TRIM3 increases the amount of p21.
TRIM3 binds to p21
We next wanted to know if TRIM3 could interact with p21. We could coimmunoprecipitate TRIM3 and p21 at endogenous levels from densly grown cultures of YH/J12 cells (Figure 5a ). We could also coprecipitate the proteins when full-length TRIM3 was overexpressed in YH/J12 or T98G cells, but not when mutants of TRIM3 lacking either the NHL domain or the RBCC domain were expressed to an even higher level (Figure 5b ). Additionally, we could reconstitute the interaction of TRIM3 with p21 using recombinant proteins produced in Escherichia.coli (Figure 5c ). Thus, TRIM3 interacts with p21, and stable interaction depends on multiple domains in both the conserved RBCC motif and in the ABP/filamin/NHL domains. (Figure 2) . Conversely, bromodeoxyuridine incorporation was reduced significantly when TRIM3 was overexpressed (Figure 6a ). When TRIM3 was overexpressed to similar levels in p21-deficient YH/J12 cells, it did not reduce proliferation; however, proliferation in these cells is so poor it is difficult to reach a conclusion about the significance of this (data not shown). Cells in which TRIM3 was overexpressed exited the cell cycle and accumulated in G0/G1 phase (Figure 6b ). However, we could not determine whether p21 levels were changed because only a fraction of the cells express TRIM3, and we could not identify any reliable immunohistochemical reagents specific for mouse p21. Thus, there is a reciprocal relationship between the expression of TRIM3 and the fraction of cells in S phase.
The ability of TRIM3 to bind to p21 and to reduce cell proliferation are inseparable To determine whether the growth suppressive activity of TRIM3 correlated with its ability to bind p21, we tried to generate a mutant that would separate these activities. To accomplish this, we deleted each conserved domain and asked if these mutants could bind to p21 when expressed in YH/J12 cells. All of the mutants with the exception of RING mutants expressed well (Figure 7a) . A mutant lacking the NHL domain was unable to bind to p21 (Figure 5b ), but the wild-type protein and the mutants individually lacking the B-box, coiled-coil or ABP domain could bind to p21 (Figure 7a ). All these proteins accumulated in the cytosol (Figure 7b ). We could also detect binding of the RING mutant to p21 by using recombinant protein in vitro (data not shown). Thus, the NHL domain of TRIM3 was necessary but not sufficient for p21 binding (Figure 5b) .
We next looked at the ability of these mutants to induce growth arrest. Whereas the NHL-deficient mutant was unable to induce growth arrest, the B-box deficient, coiled-coil deficient, and the ABP-deficient mutants could (Figure 7c ). The G371S and C736Y missense mutants that we detected in the genomic sequencing of the locus were also expressed well in cells, could bind p21 and could induce growth arrest (data not shown). Because the NHLalone mutant accumulated in the nucleus and the RING mutant was poorly expressed, we did not examine their effect on cell proliferation.
Cyclin-cdk binding sequesters p21 from TRIM3 Given that p21 is a cyclin D-cdk4 assembly factor in the RCAS-PDGF-HA/nestin-TvA model, 30 and TRIM3 can bind to p21 and suppress cell proliferation, we wanted to know if cyclin-cdks affected the interaction of TRIM3 and p21. We found that a mutant of p21 deficient in binding cyclin-cdk complexes bound better to TRIM3 than wild-type p21 in extracts containing cyclin-cdk complexes (Figure 8a ). However the wild-type p21 and the noncyclin-cdk binding mutant bound equivalently if cyclin-cdk complexes were depleted from the extract (Figure 8b) . Thus, TRIM3 binds better to p21 that was not physically associated with Immunoblot. myc-tagged TRIM3, a myc-tagged NHL-only domain, or a myc-tagged TRIM3 mutant, in which the NHL domain was removed were expressed in YH/J12 cells. The level of expression of these constructs was determined by immunoblot (labeled input: myc). p21 was immunoprecipitated from these extracts and the associated myc-TRIM3 was detected by immunoblot (labeled myc and p21). This experiment was repeated at least three times. (c) Recombinant purified GST-tagged TRIM3 or GST (indicated above the panel) was incubated with 6XHis-tagged p21 (His-p21) and reisolated on glutathione sepharose. Coomassie staining was used to detect the amount of precipitated GST and GST fusion protein.
The amount of p21 (in micromol) added is indicated at the bottom of each lane, and p21 was detected by immunoblot. This experiment was repeated at least three times with independent preparations of the recombinant proteins with similar results.
TRIM3, a tumor suppressor of the TRIM-NHL family Y Liu et al cyclin-cdk complexes, and TRIM3 and cyclin-cdk complexes might compete with each other for p21.
DISCUSSION
The evidence presented here strongly supports the interpretation that TRIM3 is a mammalian tumor suppressor whose loss can increase the incidence and promote the development of GBM. This is the first time that a member of the NHL-domain containing TRIM family has been demonstrated to have a role in tumorigenesis in mammals.
Taxonomic classification of GBM is an active area and the amplification or loss of PDGFR, EGFR, CDKN2C, PTEN, MET, CDKN2A, CDK6, CDK4, MDM2, MDM4 and PTPRD are frequently associated with different subclasses of glioma. Additionally, tumors can be subdivided on the expression of a mesenchymal or proneural signature, or on specific chromosomal abnormalities such as 1p and 19q deletions. These classifications might relate to the malignancy or therapeutic possibilities (reviewed by Brennan et al. 2 and Chen et al.
7
). However, we were unable to detect any relationship between established copy number alterations, the presence of a proneural or mesenchymal signature, or 1p/19q deletions when we attempted to correlate TRIM3 protein expression to these parameters in a small set of 40 tumors (unpublished data). Thus, expression of TRIM3 may classify GBM in a unique way and may provide insight into prognostic and therapeutic subgroups of human proneural GBM.
Loss of the TRIM-NHL proteins brat and mei-P26 in flies leads to excessive stem cell proliferation and tumor-like accumulation of neuroblasts and ovarian stem cells, respectively. 10, 11 However, there are no spontaneous tumor phenotypes reported in mammalian TRIM-NHL-deficient mice, including TRIM3. 34 Nevertheless, as we have shown, mammalian TRIM3 can suppress tumor development induced by the overexpression of PDGF in nestin-positive cells in the brain of mice.
Interestingly, the nature of the tumor induced by reducing TRIM3 was dependent on the status of p21. Reducing TRIM3 in p21-deficient mice gives rise to tumors that retain 'stem-like' expression of Id1, but reducing TRIM3 in p21-proficient mice gives rise to tumors that retain a 'progenitor-like' expression of Id1. Although the precise relationship and mechanisms of the action of TRIM3 in mammalian glial stem and progenitor cells needs to be defined, there may be therapeutic value to determining the expression of these proteins in human tumors. GBM arising from Id1 high -expressing 'stem-like' tumor cells may be less sensitive to irradiation than GBM arising from Id1 low 'progenitor-like' cells. Thus, patients who are low for TRIM3 and high for p21 might have better outcome when using modalities such as ionizing radiation.
How does TRIM3 suppress tumor growth? Other members of the TRIM-NHL family have been reported to have roles in miRNA processing and post-transcriptional regulation of myc. 11, 14, 20, 21, 35 These TRIM-NHL proteins interact with Ago1, but we have not been able to detect an interaction of TRIM3 with Ago1, at least in the p21-positive tumor cells. However, in these cells we could confirm the interaction of TRIM3 with actinin-4 and myosin V, 36 and we could demonstrate that TRIM3 can interact with p21 in an NHL-dependent manner. Thus, we propose that in these cells TRIM3 sequesters p21 away from cyclin D1-cdk4 reducing proliferation. Given the similar role of p21 in cytokine induced proliferation of bone marrow progenitors (reviewed in Abbas et al. 37 and Broxmeyer et al. 38 ) and glial progenitors 30 it seems likely that TRIM3 may have a similar tumor suppressive role in some types of leukemia as well.
Although the importance of growth-promoting activities of Kipfamily cdk inhibitors has met with skepticism, four lines of evidence suggest that these proteins have a significant growthpromoting role in some subtypes of cancer. First, mouse studies document the causal importance of cdk inhibitors for tumor progression. [39] [40] [41] [42] Second, p21 is required for cytokine-induced proliferation in bone marrow-derived progenitor cells and glial progenitor cells. 30, 37, 38 Third, correlative studies in human tissue samples suggest that the presence of cdk inhibitors can be associated with more aggressive disease. [43] [44] [45] [46] [47] [48] [49] [50] Fourth, our understanding of how tyrosine phosphorylation disrupts the inhibitory activity but preserves cyclin-cdk binding activity provides a molecular understanding of this switch in behavior. 51 Ultimately, the RCAS-PDGF-HA/nestin-TvA model allowed us to assess the crucial contribution that p21, the tyrosine phosphorylation of p21, and cyclin D1 and cdk4 make to tumor progression. [28] [29] [30] However, the ability of TRIM3 to interact with p21 only accounts for part of its growth suppressive activity, because reducing TRIM3 could promote tumor development in p21-deficient mice as well. Although the tumors that arise in p21-deficient mice are morphologically similar to those that arose in p21-proficient mice, they were clearly distinct with regard to their Id1 expression status. Given that Id1 is a proxy for the stem and progenitor nature of the cell, and p21 activities change from growth suppressor to growth promoter as cells undergo this transition, then understanding how TRIM3 works in these cells may allow us to understand how cell cycle regulators integrate with the machinery of asymmetric divisions and drive cancer.
MATERIALS AND METHODS
Cell culture and vector production
The PDGF-transformed primary glial cell line YH/J12 was described previously. 30 T98G and chicken DF-1 cell lines were purchased from American Type Culture Collection (Manassas, VA, USA) and cultured according to their directions.
The RCAS-PDGF-HA expression plasmids were described previously. 30 Mouse TRIM3 cDNA was kindly provided by Dr Andrea Ballabio. 52 myc-TRIM3 expression vector was constructed by cloning the mouse TRIM3 cDNA into pCMV-Myc vector (Clontech, Mountainview, CA, USA). myc-TRIM3 deletion constructs were generated by PCR-based DNA mutagenesis or in vitro site-directed mutagenesis as described previously. 30 The deletions encompassed the following amino-acid GST-p21 and GST-p21cy(-) were produced and purified from E. coli and the amount indicated above each lane (ng) was incubated with 0.5 mg total cell extract obtained from myc-TRIM3 transfected 293T cells. myc-TRIM3 was subsequently immunoprecipitated and the amount of TRIM3 and p21 determined by immunoblotting as indicated to the right of each panel. (b) Extracts from myc-TRIM3 expressing 293T cells were passed through either p13-sepharose to deplete cyclin-cdk comlexes or sepharose CL-4B (mock). On the left, the amount of cyclin A, cyclin D1, cdk2 and cdk4 was measured by immunoblot to assess whether the depletion was successful. On the right, 12.5 ng of recombinant substrate indicated above each lane was incubated with 0.25 mg of the depleted extracts and recovered as described.
TRIM3, a tumor suppressor of the TRIM-NHL family Y Liu et al sequences (DNHL, 421-734; NHL, 1-420; DABP, 290-420; DCC, 150-280; DB, 115-146 and DR, 22-62). Lentiviral TRIM3 shRNAs were purchased from OpenBiosystems. RCAS-TRIM3 shRNA vectors were created using the Gateway in vitro recombination system as described previously. 30 Lentiviral vectors expressing these TRIM3 shRNA were prepared as described previously. 53 RCAS vectors were prepared in DF1 cells as described previously. 30 Flow Cytometry and bromodeoxyuridine incorporation Flow cytometry analysis and bromodeoxyuridine incorporation assay were performed as described previously. 30, 54 Protein extracts, immunoblot and immunoprecipitation Protein extracts from cells were prepared as we previously described. 30 Brains were removed from euthanized mice, snap frozen in liquid nitrogen, ground to a fine powder and extracts prepared as described. 28 Immuoblot and immunoprecipitation assays were carried out as we previously described. 30 The following antibodies were used: p21 (M19 and C19, Santa Cruz, Santa Cruz, CA, USA), Flag (M2, Sigma-Aldrich, St Louis, MO, USA), c-myc (9E10, Santa Cruz), HA (Y11, Santa Cruz), tubulin (Santa Cruz), TRIM3 (BD San Diego, CA, USA and Genway, Grand Island, NY, USA) and olig2 (Millipore, Billerica, MA, USA).
Preparation of E. coli produced recombinant protein Glutathione S-transferase (GST) or His-tagged recombinant proteins were produced in E coli using GST Gene Fusion System (Amersham Pharmacia Biotech, Pittsburgh, PA, USA) and Probind Purification System (Invitrogen, Grand Island, NY, USA), respectively, according to manufactures instructions.
In vitro p21-TRIM3 binding assays A total of 0.78 mM of recombinant GST or GST-TRIM3 were combined with increasing amounts of His-p21 in a 60-ml reaction containing 50 mM TrisHCl, pH 7.5, 5 mM MgCl 2 , 1mM dithiothreitol, 2 mM phenylmethylsulfonyl fluoride, 10 mg/ml leupeptin, 10 mg/ml aprotinin, 10 mg/ml soy bean trypsin inhibitor. Following a 30-min incubation at 37 1C, GST or GST-TRIM3 was captured on a 30-ml bed volume of Glutathione-agarose beads and washed three times with the reaction buffer before adding the sample buffer. Glutathione bound proteins were resolved be SDS-polyacrylamide gel electrophoresis and GST and GST-TRIM3 detected by Coomassie blue staining, and the coprecipitating p21 was detected by immunoblot using p21 antibody (F-5 mouse monoclonal, Santa Cruz) at a 1:1000 dilution.
Histology and immunohistochemistry in mouse tumor tissue Mouse brain sections were prepared and processed as described previously. 30 The Trim3 Antibody (BD) was used as recommended by the provider. The antimouse Id1 antibody was obtained from Biocheck (BCH-1/ 37-2) and used as described by Barrett et al. 
